Welcome to our dedicated page for Tonix Pharmaceut SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing biotech disclosures can feel like decoding lab notes. Tonix Pharmaceuticals’ filings span clinical trial data, cash-runway calculations, and rapid stock issuances—details that can overwhelm even seasoned analysts. If you have ever searched for Tonix Pharmaceuticals SEC filings explained simply, you know the struggle of navigating pages of scientific jargon just to find one pipeline update.
Stock Titan’s platform solves that problem. Our AI reads every new document the moment it hits EDGAR and produces concise summaries, risk flags, and red-lined changes. Whether you need the Tonix Pharmaceuticals annual report 10-K simplified for R&D expense trends, a quick look at the Tonix Pharmaceuticals quarterly earnings report 10-Q filing, or the latest Tonix Pharmaceuticals 8-K material events explained, we deliver the context in plain English. Real-time alerts surface Tonix Pharmaceuticals Form 4 insider transactions real-time so you never miss a director’s buy or sell.
Use cases include:
- Track Tonix Pharmaceuticals insider trading Form 4 transactions to gauge management confidence.
- Dive into Tonix Pharmaceuticals earnings report filing analysis to compare cash burn versus clinical milestones.
- Monitor dilution risk by reviewing shelf registrations and capital raises.
- Spot governance changes inside the Tonix Pharmaceuticals proxy statement executive compensation.
- See every Tonix Pharmaceuticals executive stock transactions Form 4 without combing through EDGAR.
- Accelerate understanding Tonix Pharmaceuticals SEC documents with AI so you can focus on investment decisions.
All filing types, expert commentary, and AI-powered summaries—finally, the complex world of Tonix disclosures made clear.
Tonix Pharmaceuticals Holding Corp. reported a material event on
Tonix Pharmaceuticals insider purchase by Director Carolyn E. Taylor: The reported transaction shows Director Carolyn E. Taylor acquired 418 shares of Tonix Pharmaceuticals Holding Corp. common stock at a weighted-average purchase price of $36.03 per share, with individual purchase prices ranging from $35.98 to $36.05. The transaction is reported as a direct purchase under Rule 16 reporting. The filing was submitted by an attorney-in-fact on behalf of the reporting person. No derivative transactions, dispositions, or additional holdings beyond the 418 shares are disclosed in this Form 4.
Tonix Pharmaceuticals (TNXP) director James Treco purchased 250 shares of the company common stock on 08/20/2025 at a reported price of $36 per share. Following the purchase, Mr. Treco directly beneficially owned 250 shares. The transaction was reported on a Form 4 and signed by an attorney-in-fact.
Tonix Pharmaceuticals describes safety, contraindications, and dosing guidance for TONMYA (cyclobenzaprine), emphasizing serious risks and population-specific recommendations. The filing lists absolute contraindications including prior hypersensitivity and recent or concurrent MAO inhibitor use due to reports of hyperpyretic crisis, seizures, and death when combined with similar drugs. It warns of serotonin syndrome with multiple serotonergic agents and advises immediate discontinuation if symptoms occur. The company notes potential embryofetal toxicity from animal data and recommends avoiding use two weeks before conception through the first trimester and performing a pregnancy test before starting therapy. Lowered dosing is recommended for mild hepatic impairment (2.8 mg once daily), and use is not recommended in moderate or severe hepatic impairment. Other cautions address CNS depression, anticholinergic effects, oral mucosal reactions, limited data in elderly and pediatric populations, and lactation considerations.
FAQ
What is the current stock price of Tonix Pharmaceut (TNXP)?
What is the market cap of Tonix Pharmaceut (TNXP)?
